B O O K - American College of Rheumatology

Come to booth #1429
Approved in RA since 1998.
ENBREL is indicated for reducing signs and symptoms, inducing major clinical
response, inhibiting the progression of structural damage, and improving physical
function in patients with moderately to severely active rheumatoid arthritis (RA).
ENBREL can be initiated in combination with methotrexate (MTX) or used alone.
See Important Safety Information on the adjacent page concerning the risks of
serious infections, including TB and other opportunistic infections, lymphoma
and other malignancies, and other serious adverse events.
You are part of Generation ENBREL, a
generation of rheumatologists practicing
since the approval of ENBREL. Join your
peers at Booth #1429 to take a journey
through our years of experience. Review
data in moderate to severe rheumatoid
arthritis and in psoriatic arthritis.
Look for the ENBREL symposium,
sponsored by Amgen and Pfizer,
coming up this week.
GeorGia world
ConGress Center
november 6–11, 2010, atlanta, Ga
Please see Brief Summary of Prescribing Information on the following pages.
EXPERIENCE STARTS HERE